Atorvia develops potential kidney-disease medicines using protein research and machine-learning-assisted drug development.
Atorvia is a preclinical biotechnology company developing potential medicines for kidney disease. Its research combines the study of protein function with machine learning to identify targets and develop drugs intended for kidney cells.
One program has focused on preventing kidney failure associated with cardiac surgery. Atorvia received laboratory access and mentorship through the University of Toronto Mississauga’s Blue Ticket program.
Loading profile details…
Drug Discovery · Business involvement
As of 2026-11-09
Loading recent changes…
Editorial profile by MoneyMakers. Sources reviewed .
Brand marks identify the organization. Logo from the official website.
Founder
Founder of kidney-therapy developer Atorvia.
View personal profile